Lab Literacy / Dose Titration: When Labs Drive the Dose (and When They Don't)
9 min readMost of what people call "titration" in the peptide space is not titration at all. It is a fixed escalation schedule with a predetermined end point. You start low, you increase on a timer, and you stop when you hit the target dose.
That is how GLP-1 drugs work. It is how tesamorelin works. The schedule is printed in the protocol. No lab result changes it.
There is exactly one major peptide class where a lab value directly drives the dose: the growth-hormone axis. IGF-1 is the biomarker, and the guidelines are explicit — increase the dose, check IGF-1, increase again, stop when you hit the upper end of the age-adjusted normal range. The lab is in the driver's seat.
Understanding which model applies to which compound is one of the more practically important distinctions in reading peptide research, because it determines whether a lab panel is central to the protocol or peripheral to it.
The Endocrine Society guidelines (2011, updated by AACE in 2019) for growth hormone replacement lay out a specific titration logic. The diagnosis of adult growth hormone deficiency requires a stimulation test — insulin tolerance testing or GHRH plus arginine — not just a low IGF-1. Once the diagnosis is established:
This is genuine lab-driven dosing. The IGF-1 result at each check point determines whether the next visit raises the dose, holds it, or reduces it. The target is not a fixed mg amount — it is a lab range, and the mg amount is whatever gets you there.
The reason is pharmacological. GH-axis peptides — tesamorelin, CJC-1295, ipamorelin, MK-677 — all act by increasing growth hormone secretion, which raises IGF-1. But the relationship between dose and IGF-1 is not linear, and it varies significantly between individuals based on age, sex, baseline secretion, and receptor sensitivity. A fixed dose that puts a 25-year-old male at the top of his IGF-1 range might put a 60-year-old female well above hers. The lab result is the only way to know where you actually sit on the curve.
The Nass 2008 trial of MK-677 in elderly adults illustrates the principle. Participants started with a mean IGF-1 of 141 mcg/L — low for younger adults, but the trial enrolled people aged 60–81, where the normal range is lower. After two years on 25 mg/day oral MK-677, IGF-1 rose to a mean of 219 mcg/L — an increase, but one that remained within or near the age-adjusted range for that population. Fasting glucose rose modestly. No participant developed diabetes over the two-year period. The dose was fixed in this trial, but the rationale for the dose selection was grounded in the expected IGF-1 response for the age group enrolled.
Semaglutide and tirzepatide use a completely different approach. The dose escalation is predetermined and runs on a timer:
| Drug | Program | Escalation schedule | Top dose |
|---|---|---|---|
| Semaglutide | SUSTAIN (diabetes) | 0.25 → 0.5 → 1.0 mg, q4wk steps | 1.0 mg |
| Semaglutide | STEP (obesity) | Same steps, continued upward | 2.4 mg |
| Tirzepatide | SURMOUNT (obesity) | 2.5 mg q4wk steps | 10 or 15 mg |
Every four weeks, the dose goes up. There is no lab check that pauses the escalation. There is no biomarker that says "hold at this dose." The schedule runs until you reach the target dose, and the only reason to deviate is gastrointestinal intolerance — nausea, vomiting, diarrhea — not a lab value.
The reason is straightforward: there is no reliable biomarker that correlates well enough with GLP-1 efficacy to serve as a titration guide. GLP-1 agonists work through multiple mechanisms — appetite suppression, gastric emptying delay, direct pancreatic effects — and no single lab value captures the aggregate response. HbA1c falls as glucose control improves, but HbA1c is a 90-day average. You cannot use it to make dose decisions at a four-week interval. Fasting glucose is too variable day to day. There is no GLP-1 equivalent of IGF-1 for the GH axis.
So the trials used a fixed schedule instead — start low to establish tolerability, escalate on a clock, and accept that the dose is determined by the protocol rather than by the patient's biology. The labs in GLP-1 trials (HbA1c, fasting glucose, lipase, amylase, CMP) are there for safety monitoring and endpoint measurement, not for dose decisions.
Tesamorelin takes the fixed approach even further: there is no titration at all. The FDA-approved dose is 2 mg/day, administered as a single daily injection. You start at 2 mg. You stay at 2 mg.
This makes sense in the context of the trial design described in the previous article. The primary endpoint was VAT reduction at 26 weeks, measured by CT scan. The dose was selected during dose-finding studies before the pivotal trial. Once that dose was established, the question was whether it worked at that level — not whether a different dose would work better for a given individual.
IGF-1 is still monitored in tesamorelin protocols, but as a safety and target-engagement marker, not as a titration driver. The dose does not change based on the IGF-1 result. This is fundamentally different from the GH-replacement model, where IGF-1 is the titration driver.
| Feature | GH-axis peptides (per guidelines) | GLP-1 agonists | Tesamorelin |
|---|---|---|---|
| Dose decision driven by | IGF-1 lab result | Fixed schedule (timer) | Fixed dose (no titration) |
| Monitoring cadence during adjustment | IGF-1 every 4–8 weeks | q4wk clinic visits (schedule, not labs) | Periodic IGF-1 (safety only) |
| Reason for de-escalation | IGF-1 above target range | GI intolerance | Not built into protocol |
| Target | Upper-normal IGF-1 for age/sex | Predetermined mg ceiling | 2 mg/day |
| Key safety labs | Glucose, HbA1c, thyroid, prolactin | Lipase, amylase, calcitonin, CMP | IGF-1, glucose, HbA1c, lipids, CMP |
When you encounter a peptide protocol, the first question about dosing is: is this a lab-driven titration or a fixed schedule? The answer tells you which labs actually matter and which are just background monitoring.
For GH-axis peptides, IGF-1 is the central lab value. The dose exists to put IGF-1 in the right range. If a protocol describes GH-axis peptide dosing without mentioning IGF-1 monitoring, or uses a fixed dose without IGF-1 tracking, it is not following the titration model the clinical guidelines describe.
For GLP-1 agonists and tesamorelin, the labs are important for safety — pancreatitis surveillance, glucose monitoring, organ function — but they do not drive the dose. A protocol that claims to "titrate" a GLP-1 agonist based on lab values is describing something the pivotal trials did not do.
The distinction is not subtle. In one model, the lab result is the decision point. In the others, the schedule is the decision point and the lab is watching for problems. Conflating the two models leads to protocols that look rigorous — lots of lab checks — but are built on the wrong logic for the compound they describe.
This article is for educational purposes and is not medical advice. It describes how published clinical trials and clinical guidelines approach dose titration. It does not recommend any peptide, test, dose, or protocol. Decisions about treatment belong with a qualified clinician who knows your medical history.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.